Regulatory enzymes of mitochondrial beta-oxidation as targets for treatment of the metabolic syndrome.
Level 5 - mechanism / opinion, no new human data
Narrative review of biochemical pathways and pharmacological targets without primary human data.
PubMed 19694967 · doi:10.1111/j.1467-789X.2009.00642.x
What was done
Narrative review synthesizing mechanistic evidence on the adenosine monophosphate-activated protein kinase (AMPK)-acetyl-CoA carboxylase (ACC)-carnitine palmitoyltransferase 1 (CPT1) regulatory axis and evaluating ACC2, systemic CPT1, and brain CPT1C as therapeutic targets for metabolic syndrome.
What was found
The abstract reports no quantitative data or statistical comparisons. It describes that malonyl-CoA from ACC2 inhibits CPT1, regulating mitochondrial long-chain fatty acid oxidation; that liver CPT1 inhibition causes side effects including hepatic steatosis; and that stimulating CPT1 activity (via ACC2 inhibition or PPAR activation) enhances peripheral fatty acid oxidation to improve insulin sensitivity.
Why it matters
The paper outlines mechanistic strategies to stimulate mitochondrial beta-oxidation for treating metabolic syndrome while explaining the risks associated with direct hepatic CPT1 inhibition.
Limits
Narrative review design containing mechanistic reasoning rather than primary empirical or clinical trial data. No sample sizes, study counts, effect estimates, or clinical safety outcomes are provided in the abstract.
Cited by
- supports Transport of fatty acids into mitochondria for beta-oxidation via carnitine palmitoyltransferase (CPT) transporters is regulated by malonyl-CoA.